AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|
21 C
New York
Wednesday, September 2, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026MCO-010 BLA for retinitis pigmentosa is eligible for priority review...

Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable...

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

AKANTIOR® is anticipated to become available to Spanish patients on 1st August Spain is the first Country in the world to approve the pricing and...

Anavar for Women: Exploring the Rise of Anvarol Performance Supplement Among Female Bodybuilders and Athletes From CrazyBulk

Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk. 
Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk.

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers, Sarepta, and Petco and Encourages Investors...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS), Sarepta (SRPT), or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN), UroGen (URGN), Red Cat (RCAT), or Fortrea (FTRE) To Contact Him Directly To Discuss Their Options

KIF18A Targeting Therapies FDA EMA Approval Clinical Trials By Indication Company Country Drug Class Report

Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies 
Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies

Strive Compounding Pharmacy Hosts “Dinner with the Doc” Initiative, Offering Insight into Personalized Medicine

Helping providers understand compounding to deliver more personalized patient care. GILBERT, Ariz., July 11, 2025 /PRNewswire/ -- Strive Compounding Pharmacy, a leader in personalized healthcare...

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Master Injector Alexander Tirado Brings Passion and Knowledge as New Wellness Director at Parkland Medspa and Wellness Center

PARKLAND, Fla., July 11, 2025 /PRNewswire/ -- Master injector Alexander Tirado, who brings unmatched passion and intimate knowledge of multiple disciplines, has been appointed...

Safest Steroid for Muscle Growth and Bodybuilding – Clinical Evidence and Safety Behind CrazyBulk’s Bulking Steroids

New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) --

For decades, the use of muscle building steroids has been a driving force behind the pursuit of muscle growth and physical prowess among bodybuilders, athletes, and sports professionals. 

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers